相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
John W. Eikelboom et al.
JAMA CARDIOLOGY (2017)
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures
A. Tripodi
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study
S. Testa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics
Sophie Testa et al.
THROMBOSIS RESEARCH (2016)
Are New Oral Anticoagulant Dosing Recommendations Optimal for All Patients?
J. Robert Powell
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Targeted Anti-Anticoagulants
Kenneth A. Bauer
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations
Jonathan Douxfils et al.
BIOMED RESEARCH INTERNATIONAL (2015)
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Emilia Antonucci et al.
PLOS ONE (2015)
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Jan Beyer-Westendorf et al.
BLOOD (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Cardioembolic stroke in a patient taking Dabigatran Etexilate: The first case report of clinical and pharmacologic resistance
Joao Sargento-Freitas et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
Inna Y. Gong et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
T. Baglin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Ischemic Stroke in an Obese Patient Receiving Dabigatran
Lorenz Breuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Joachim Stangier et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Walter Ageno et al.
CHEST (2012)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma
Meyer Michel Samama et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
Bengt I. Eriksson et al.
CLINICAL PHARMACOKINETICS (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
分享论文
